Home LiteratureArticle Details
PMID: 17881443 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.

Journal of virology ·Vol. 81 ·No. 23 ·2007-12-00 ·Pages 13112-24

Wang T, Tian C, Zhang W, Luo K, Sarkis PT, Yu L, Liu B, Yu Y, Yu XF

Abstract

Cytidine deaminase APOBEC3G (A3G) has broad antiviral activity against diverse retroviruses and/or retrotransposons, and its antiviral functions are believed to rely on its encapsidation into virions in an RNA-dependent fashion. However, the cofactors of A3G virion packaging have not yet been identified. We demonstrate here that A3G selectively interacts with certain polymerase III (Pol III)-derived RNAs, including Y3 and 7SL RNAs. Among A3G-binding Pol III-derived RNAs, 7SL RNA was preferentially packaged into human immunodeficiency virus type 1 (HIV-1) particles. Efficient packaging of 7SL RNA, as well as A3G, was mediated by the RNA-binding nucleocapsid domain of HIV-1 Gag. A3G mutants that had reduced 7SL RNA binding but maintained wild-type levels of mRNA and tRNA binding were packaged poorly and had impaired antiviral activity. Reducing 7SL RNA packaging by overexpression of SRP19 proteins inhibited 7SL RNA and A3G virion packaging and impaired its antiviral function. Thus, 7SL RNA that is encapsidated into diverse retroviruses is a key cofactor of the antiviral A3G. This selective interaction of A3G with certain Pol III-derived RNAs raises the question of whether A3G and its cofactors may have as-yet-unidentified cellular functions.

MeSH Terms
APOBEC-3G Deaminase Cell Line Cytidine Deaminase/genetics,immunology,metabolism HIV-1/immunology Humans Mutation RNA, Small Cytoplasmic/physiology Signal Recognition Particle/physiology Virus Assembly/immunology gag Gene Products, Human Immunodeficiency Virus
Chemicals
7SL RNA RNA, Small Cytoplasmic Signal Recognition Particle gag Gene Products, Human Immunodeficiency Virus APOBEC-3G Deaminase APOBEC3G protein, human Cytidine Deaminase
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Wang Tao
Department of Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.
Tian Chunjuan
Zhang Wenyan
Luo Kun
Sarkis Phuong Thi Nguyen
Yu Lillian
Liu Bindong
Yu Yunkai
Yu Xiao-Fang
References (79)
79 references, click to expand
  1. Targeting proteins to membranes: structure of the signal recognition particle.
    Curr Opin Struct Biol. 2005 Apr;15(2):213-20 PMID: 15837181
  2. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function.
    J Biol Chem. 2005 May 13;280(19):18573-8 PMID: 15781449
  3. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    J Virol. 2005 Aug;79(15):9579-87 PMID: 16014920
  4. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.
    Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9854-9 PMID: 16000409
  5. Down-regulation of 7SL RNA expression and impairment of vesicular protein transport pathways by Leishmania infection of macrophages.
    J Biol Chem. 2005 Aug 12;280(32):29364-73 PMID: 15955815
  6. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.
    Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11444-9 PMID: 16076960
  7. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.
    J Virol. 2005 Sep;79(17):10978-87 PMID: 16103149
  8. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.
    Virology. 2005 Sep 1;339(2):281-8 PMID: 15993456
  9. Nonrandom packaging of host RNAs in moloney murine leukemia virus.
    J Virol. 2005 Nov;79(21):13528-37 PMID: 16227273
  10. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    J Virol. 2006 Jan;80(2):875-82 PMID: 16378989
  11. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
    Nucleic Acids Res. 2006;34(1):89-95 PMID: 16407327
  12. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Curr Biol. 2006 Mar 7;16(5):480-5 PMID: 16527742
  13. 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles.
    RNA. 2006 Apr;12(4):542-6 PMID: 16489186
  14. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif.
    Virology. 2006 Jun 5;349(2):290-9 PMID: 16530799
  15. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
    PLoS Pathog. 2006 May;2(5):e41 PMID: 16699599
  16. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    J Virol. 2007 Jul;81(13):7238-48 PMID: 17428847
  17. Inhibition of hepatitis B virus replication by APOBEC3G.
    Science. 2004 Mar 19;303(5665):1829 PMID: 15031497
  18. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Nat Struct Mol Biol. 2004 May;11(5):435-42 PMID: 15098018
  19. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Nucleic Acids Res. 2004;32(8):2421-9 PMID: 15121899
  20. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
    J Virol. 2004 Jun;78(11):6073-6 PMID: 15141007
  21. The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity.
    J Mol Med (Berl). 2004 Apr;82(4):232-9 PMID: 15168680
  22. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
    EMBO J. 2004 Jun 16;23(12):2451-8 PMID: 15152192
  23. The interaction between HIV-1 Gag and APOBEC3G.
    J Biol Chem. 2004 Aug 6;279(32):33177-84 PMID: 15159405
  24. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Curr Biol. 2004 Aug 10;14(15):1385-91 PMID: 15296757
  25. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
    Curr Biol. 2004 Aug 10;14(15):1392-6 PMID: 15296758
  26. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
    J Biol Chem. 2004 Aug 13;279(33):34083-6 PMID: 15215254
  27. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    J Biol Chem. 2004 Aug 20;279(34):35822-8 PMID: 15210704
  28. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
    Biochem Biophys Res Commun. 2004 Aug 27;321(3):566-73 PMID: 15358144
  29. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Virology. 2004 Oct 25;328(2):163-8 PMID: 15464836
  30. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol. 2004 Nov;78(21):11841-52 PMID: 15479826
  31. APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
    J Virol. 2004 Nov;78(21):12058-61 PMID: 15479846
  32. Nucleic acid and proteins isolated from the Rauscher mouse leukemia virus (MLV).
    Proc Natl Acad Sci U S A. 1966 Jan;55(1):219-27 PMID: 5220869
  33. The low molecular weight RNAs of Rous sarcoma virus. II. The 7 S RNA.
    Virology. 1970 Dec;42(4):927-37 PMID: 4321311
  34. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8780-5 PMID: 16728505
  35. A zinc-binding region in Vif binds Cul5 and determines cullin selection.
    J Biol Chem. 2006 Jun 23;281(25):17259-65 PMID: 16636053
  36. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
    J Biol Chem. 2006 Jun 23;281(25):16837-41 PMID: 16648136
  37. APOBEC3 proteins inhibit human LINE-1 retrotransposition.
    J Biol Chem. 2006 Aug 4;281(31):22161-72 PMID: 16735504
  38. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    J Virol. 2006 Sep;80(17):8450-8 PMID: 16912295
  39. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
    J Biol Chem. 2006 Sep 29;281(39):29105-19 PMID: 16887808
  40. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15588-93 PMID: 17030807
  41. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
    J Virol. 2006 Dec;80(23):11710-22 PMID: 16971427
  42. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G.
    FASEB J. 2007 Jan;21(1):217-22 PMID: 17135358
  43. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules.
    J Virol. 2007 Mar;81(5):2165-78 PMID: 17166910
  44. Protein-induced conformational changes of RNA during the assembly of human signal recognition particle.
    J Mol Biol. 2007 Mar 16;367(1):187-203 PMID: 17254600
  45. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
    J Virol. 2007 Apr;81(8):3807-15 PMID: 17267497
  46. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
    J Biol Chem. 2007 Apr 20;282(16):11667-75 PMID: 17272283
  47. Model structure of human APOBEC3G.
    PLoS One. 2007;2(4):e378 PMID: 17440614
  48. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker.
    J Virol. 2007 May;81(10):5000-13 PMID: 17344295
  49. Characterization of ribonucleic acid from visna virus.
    J Virol. 1971 May;7(5):582-7 PMID: 4997549
  50. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
    J Virol. 2007 Jul;81(13):7099-110 PMID: 17428871
  51. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
    Genomics. 2002 Mar;79(3):285-96 PMID: 11863358
  52. Crystal structure of SRP19 in complex with the S domain of SRP RNA and its implication for the assembly of the signal recognition particle.
    Mol Cell. 2002 Jun;9(6):1251-61 PMID: 12086622
  53. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  54. Hypermutation of HIV-1 DNA in the absence of the Vif protein.
    Science. 2003 May 16;300(5622):1112 PMID: 12750511
  55. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  56. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  57. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  58. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Cell. 2003 Jul 11;114(1):21-31 PMID: 12859895
  59. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Mol Cell. 2003 Sep;12(3):591-601 PMID: 14527406
  60. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Nat Med. 2003 Nov;9(11):1404-7 PMID: 14528300
  61. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Nat Med. 2003 Nov;9(11):1398-403 PMID: 14528301
  62. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Science. 2003 Nov 7;302(5647):1056-60 PMID: 14564014
  63. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Curr Biol. 2003 Nov 11;13(22):2009-13 PMID: 14614829
  64. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    J Virol. 2004 Feb;78(4):2072-81 PMID: 14747572
  65. Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D.
    J Virol. 1974 Jul;14(1):152-61 PMID: 4134468
  66. Properties of feline leukemia virus. III. Analysis of the RNA.
    J Virol. 1975 Sep;16(3):535-45 PMID: 169389
  67. Low-molecular-weight RNAs of Moloney murine leukemia virus: identification of the primer for RNA-directed DNA synthesis.
    J Virol. 1977 Mar;21(3):1031-41 PMID: 66325
  68. Selective packaging of host tRNA's by murine leukemia virus particles does not require genomic RNA.
    J Virol. 1979 Jan;29(1):328-35 PMID: 219227
  69. Variable tRNA content in HIV-1IIIB.
    Biochem Biophys Res Commun. 1992 Jun 30;185(3):1005-15 PMID: 1627125
  70. Retroviral restriction by APOBEC proteins.
    Nat Rev Immunol. 2004 Nov;4(11):868-77 PMID: 15516966
  71. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
    Genes Dev. 2004 Dec 1;18(23):2861-6 PMID: 15574592
  72. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
    Genes Dev. 2004 Dec 1;18(23):2867-72 PMID: 15574593
  73. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    J Biol Chem. 2004 Dec 17;279(51):53379-86 PMID: 15466872
  74. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
    Nature. 2005 Jan 27;433(7024):430-3 PMID: 15674295
  75. Editing at the crossroad of innate and adaptive immunity.
    Science. 2005 Feb 18;307(5712):1061-5 PMID: 15718460
  76. Complementary function of the two catalytic domains of APOBEC3G.
    Virology. 2005 Mar 15;333(2):374-86 PMID: 15721369
  77. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Nucleic Acids Res. 2005;33(6):1913-23 PMID: 15809227
  78. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    Curr Biol. 2005 Apr 12;15(7):661-6 PMID: 15823539
  79. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
    J Virol. 2005 May;79(9):5870-4 PMID: 15827203
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2007-12-00
Epub
2007-00-19
Pages
13112-24
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2169093
Subset
IM
Grants
NIAID NIH HHS · R01 AI062644 · United States
NIAID NIH HHS · R01 AI062644-03 · United States
NIAID NIH HHS · R56 AI062644 · United States
NIAID NIH HHS · AI062644 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com